Antisense oligonucleotides against tenascin for the treating of vitiligo

Abstract

Antisense oligonucleotides against tenascin for the treatment of vitiligo The invention relates to specific, optionally modified oligonucleotides having a length of up to 18 nucleotides, which correspond to sections of tenascin-coding sequences or can bind to these sequences, to their preparation and to the use thereof, for example for the specific inhibition of the expression of tenascin and for the production of pharmaceuticals which can be used for the treatment of vitiligo.

1 - 23 . (canceled)  
     
     
         24 . An oligonucleotide or physiologically tolerable salt thereof, comprising a sequence selected from the group consisting of SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 17, SEQ ID NO. 19, and SEQ ID NO. 20, wherein the oligonucleotide has a maximum length of 7 to 17 nucleotide units:  
     
     
         25 . The oligonucleotide of  claim 24 , wherein the oligonucleotide consists of SEQ ID NO: 13.  
     
     
         26 . The oligonucleotide of  claim 24 , wherein the oligonucleotide consists of SEQ ID NO: 14.  
     
     
         27 . The oligonucleotide of  claim 24 , wherein the oligonucleotide consists of SEQ ID NO:15.  
     
     
         28 . The oligonucleotide of  claim 24 , wherein the oligonucleotide consists of SEQ ID NO: 16.  
     
     
         29 . The oligonucleotide of  claim 24 , wherein the oligonucleotide consists of SEQ ID NO: 17.  
     
     
         30 . The oligonucleotide of  claim 24 , wherein the oligonucleotide consists of SEQ ID NO:19.  
     
     
         31 . The oligonucleotide of  claim 24 , wherein the oligonucleotide consists of SEQ ID NO:20.